The metalloproteinase (MP) family of zinc-dependent proteases, including matrix
metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs), and a disintegrin …

Antibody display technologies enable the successful isolation of antigen-specific antibodies
with therapeutic potential. The key feature that facilitates the selection of an antibody with …

Engineering and study of protein function by directed evolution has been limited by the
technical requirement to use global mutagenesis or introduce DNA libraries. Here, we …

Monoclonal antibodies are being developed as therapeutics to complement drugs and
vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies …

Antibodies as ideal therapeutic and diagnostic molecules are among the top-selling drugs
providing considerable efficacy in disease treatment, especially in cancer therapy …

The remarkable progress in engineering and clinical development of therapeutic antibodies
in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by …

Phage display technology has played a key role in the remarkable progress of discovering
and optimizing antibodies for diverse applications, particularly antibody-based drugs. This …

G-protein-coupled receptors (GPCRs) are activated by a diverse range of ligands, from large
proteins and proteases to small peptides, metabolites, neurotransmitters and ions. They are …

Nanomedicines have significant potential for cancer treatment. Although the majority of
nanomedicines currently tested in clinical trials utilize simple, biocompatible liposome …

Peptide aptamers are small combinatorial proteins that are selected to bind to specific sites
on their target molecules. Peptide aptamers consist of short, 5-20 amino acid residues long …